CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Mexiletine hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000793
NCT00000793Phase 2Completed

A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Oct 29, 2021

In Brief

A Phase 2 clinical trial evaluating Mexiletine hydrochloride, Benztropine mesylate, and 1 other intervention for HIV Infections and Peripheral Nervous System Disease. Completed, across 37 sites in 2 countries.

Detailed Summary

To assess the efficacy, safety, and tolerability of amitriptyline hydrochloride versus mexiletine hydrochloride in reducing pain intensity in patients with HIV-related painful peripheral neuropathy. No large-scale controlled clinical trials of symptomatic therapy for painful HIV-related neuropathy have been attempted. Both amitriptyline and mexiletine have been useful in the management of painful neuropathies; however, both are associated with certain toxicities. In this comparative study of amitriptyline and mexiletine, benztropine mesylate also will be included as an active placebo to mimic the side effects of the study drugs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTanzania, United States

Timeline

Phase 2CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionOct 1, 1997
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Mexiletine hydrochloridedrug

Benztropine mesylatedrug

Amitriptyline hydrochloridedrug